NCT07477743 2026-03-17
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors
HC Biopharma Inc.
Phase 1 Recruiting
Clinical Trials
60 trialsNCT05381909 2026-02-20
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT02597036 2025-10-23
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT05107674 2025-09-09
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT04047862 2025-08-22
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1 Completed
NCT03537690 2025-08-12
FID-007 in Treating Participants With Advanced Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT05978492 2025-04-24
A Study of TXN10128 in Subjects With Solid Tumors
Txinno Bioscience Inc.
Phase 1 Recruiting
NCT04761601 2024-03-13
First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
1200 Pharma, LLC
Phase 1 Terminated
NCT03892018 2023-05-22
The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol
Athenex, Inc.
Phase 1 Terminated
NCT03588039 2023-05-19
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
Athenex, Inc.
Phase 1 Terminated
NCT01407562 2022-09-28
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
Phase 1 Terminated
NCT03894540 2022-09-13
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
Ipsen
Phase 1 Terminated
NCT04742036 2022-08-19
Capivasertib China PK Study
AstraZeneca
Phase 1 Completed
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT03430882 2022-06-21
Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04035473 2022-04-13
A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Athenex, Inc.
Phase 1 Completed
NCT02730481 2021-09-13
A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies
Athenex, Inc.
Phase 1 Completed
NCT04802980 2021-07-28
A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor
Huabo Biopharm Co., Ltd.
Phase 1 Unknown
NCT01240655 2020-12-19
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT03920839 2020-04-24
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Incyte Corporation
Phase 1 Withdrawn
NCT01548924 2020-04-17
Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase 1 Terminated
NCT02430311 2019-07-31
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
AstraZeneca
Phase 1 Completed
NCT02341456 2019-03-25
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02122770 2019-01-07
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT00768469 2018-11-19
Study Evaluating Safety And Tolerability, Solid Tumor
Puma Biotechnology, Inc.
Phase 1 Completed
NCT00004863 2018-09-10
Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
Montefiore Medical Center
Phase 1 Completed
NCT03503604 2018-04-20
A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
SuZhou Stainwei Biotech Inc.
Phase 1 Unknown
NCT01494688 2018-03-16
A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT00891605 2017-11-21
Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT01617928 2017-11-20
A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT02593708 2017-11-17
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
University of California, San Francisco
Phase 1 Terminated
NCT01297452 2017-03-31
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00003899 2016-10-04
Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT01930292 2016-03-24
Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies
Debiopharm International SA
Phase 1 Terminated
NCT01245543 2015-11-02
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Withdrawn
NCT00005078 2015-06-08
Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
City of Hope Medical Center
Phase 1 Completed
NCT00009802 2013-12-19
Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors
University of Pittsburgh
Phase 1 Completed
NCT00009828 2013-12-19
Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors
University of Pittsburgh
Phase 1 Withdrawn
NCT00002939 2013-09-05
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
University of Chicago
Phase 1 Completed
NCT00003555 2013-06-26
Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003004 2013-06-24
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00003242 2013-06-24
Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00003742 2013-06-21
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00030368 2013-06-04
Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002587 2013-06-03
Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00054548 2013-05-16
Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00004173 2013-05-15
Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00009932 2013-05-15
Combination Chemotherapy in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00287937 2013-02-07
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed